NCT06572319 2024-08-27Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ PatiensZhejiang Cancer HospitalPhase 1/2 Recruiting35 enrolled
NCT05982834 2023-08-09Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGCFudan UniversityPhase 1/2 Unknown43 enrolled